BE808354A - Proteine fixee sur un support et procede de fabrication - Google Patents

Proteine fixee sur un support et procede de fabrication

Info

Publication number
BE808354A
BE808354A BE138625A BE138625A BE808354A BE 808354 A BE808354 A BE 808354A BE 138625 A BE138625 A BE 138625A BE 138625 A BE138625 A BE 138625A BE 808354 A BE808354 A BE 808354A
Authority
BE
Belgium
Prior art keywords
manufacturing
support
protein fixed
protein
fixed
Prior art date
Application number
BE138625A
Other languages
English (en)
French (fr)
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2260185A external-priority patent/DE2260185C3/de
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of BE808354A publication Critical patent/BE808354A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/18—Multi-enzyme systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F289/00—Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds not provided for in groups C08F251/00 - C08F287/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087—Acrylic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BE138625A 1972-12-08 1973-12-07 Proteine fixee sur un support et procede de fabrication BE808354A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2260185A DE2260185C3 (de) 1971-06-09 1972-12-08 Trägergebundenes Protein und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
BE808354A true BE808354A (fr) 1974-06-07

Family

ID=5863935

Family Applications (1)

Application Number Title Priority Date Filing Date
BE138625A BE808354A (fr) 1972-12-08 1973-12-07 Proteine fixee sur un support et procede de fabrication

Country Status (12)

Country Link
US (1) US3969287A (cg-RX-API-DMAC7.html)
JP (1) JPS5749197B2 (cg-RX-API-DMAC7.html)
BE (1) BE808354A (cg-RX-API-DMAC7.html)
CA (1) CA1023287A (cg-RX-API-DMAC7.html)
CH (1) CH619003A5 (cg-RX-API-DMAC7.html)
DK (1) DK141555C (cg-RX-API-DMAC7.html)
HU (1) HU169972B (cg-RX-API-DMAC7.html)
IL (1) IL43476A (cg-RX-API-DMAC7.html)
IT (1) IT1045912B (cg-RX-API-DMAC7.html)
SE (1) SE420498B (cg-RX-API-DMAC7.html)
SU (1) SU524521A3 (cg-RX-API-DMAC7.html)
ZA (1) ZA739318B (cg-RX-API-DMAC7.html)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593992A5 (cg-RX-API-DMAC7.html) * 1972-12-23 1977-12-30 Roehm Gmbh
GB1550819A (en) * 1975-06-04 1979-08-22 Nat Res Dev Polymeric support for biogically active materials
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4108804A (en) * 1975-12-23 1978-08-22 Toru Seita Process for preparation of chromatography solid supports comprising a nucleic acid base-epoxy group containing porous gel
US4046723A (en) * 1976-04-22 1977-09-06 The Dow Chemical Company Azide bonding of a protein to a latex
US4206261A (en) * 1976-06-09 1980-06-03 Schenectady Chemicals, Inc. Water-soluble polyester imide resin wire coating process
US4179423A (en) * 1976-06-09 1979-12-18 Schenectady Chemicals, Inc. Water-soluble polyester imide resins
US4045384A (en) * 1976-07-23 1977-08-30 The Dow Chemical Company Method for forming an amide bond between a latex and protein
DE2708018A1 (de) * 1977-02-24 1978-09-07 Boehringer Mannheim Gmbh An polyamid fixiertes biologisch aktives protein und verfahren zu seiner herstellung
IT1107772B (it) * 1977-08-22 1985-11-25 Cancer Res Inst Royal Procedimento per la produzione di complessi macromolecolari prodotto ottenuto e composizioni farmaceutiche che lo contengono come ingrediente attivo
US4206286A (en) * 1977-11-14 1980-06-03 Technicon Instruments Corporation Immobilization of proteins on inorganic supports
US4338398A (en) * 1979-03-20 1982-07-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Immobilization of starch degrading enzymes
US4415665A (en) * 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
DE3126551C2 (de) * 1981-07-04 1983-12-15 Rolf Dr. 8700 Würzburg Siegel Herstellungsverfahren für Materialien zur Immobilisierung von Proteinen und Kohlenhydratgruppen
US4506019A (en) * 1982-09-24 1985-03-19 Leeco Diagnostics, Inc. Activated polymer container means and assay method employing the same
US4596777A (en) * 1983-08-10 1986-06-24 E. R. Squibb & Sons, Inc. Process for preparing (3S)-3-[[[2-(protected or unprotected amino)-4-thiazolyl]acetyl]amino]-2-oxo-1-azetidinesulfonic acid and 4-substituted derivatives thereof
US4511478A (en) * 1983-11-10 1985-04-16 Genetic Systems Corporation Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides
US4711840A (en) * 1984-01-27 1987-12-08 Genetic Systems Corporation Polymerization-induced separation immunoassays
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
EP0142810B1 (en) * 1983-11-10 1994-02-16 Genetic Systems Corporation Polymerizable compounds integrally containing antibodies and their uses in polymerization induced separation immunoassays
US4609707A (en) * 1983-11-10 1986-09-02 Genetic Systems Corporation Synthesis of polymers containing integral antibodies
US4843010A (en) * 1983-11-10 1989-06-27 Genetic Systems Corporation Polymerization-induced separation immunoassays
JPH0820447B2 (ja) * 1984-01-27 1996-03-04 ジェネティック システムズ コーポレーション 液体混合物から物質を分離する方法及び免疫評価法
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4749647A (en) * 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
ES2044933T3 (es) * 1986-08-07 1994-01-16 Minnesota Mining & Mfg Emulsiones de productos quimicos fluorados, biologicamente activas y estables.
US4808530A (en) * 1986-09-05 1989-02-28 The Ohio State University Protein immobilization by adsorption of a hydrophobic amidine protein derivative to a hydrophobic surface
US4885250A (en) * 1987-03-02 1989-12-05 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5063109A (en) * 1988-10-11 1991-11-05 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DK0473961T3 (da) * 1990-08-15 1996-07-01 Abbott Lab Immunoassay-reagenser og fremgangsmåde til bestemmelse af cyklosporin
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5482996A (en) * 1993-12-08 1996-01-09 University Of Pittsburgh Protein-containing polymers and a method of synthesis of protein-containing polymers in organic solvents
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6045797A (en) * 1994-03-14 2000-04-04 New York University Medical Center Treatment or diagnosis of diseases or conditions associated with a BLM domain
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5736624A (en) * 1994-12-02 1998-04-07 Abbott Laboratories Phosphatase activated crosslinking, conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5807989A (en) * 1994-12-23 1998-09-15 New York University Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
US6300482B1 (en) * 1995-01-03 2001-10-09 Max-Flanck-Gesellschaft Zuer For{Overscore (D)}Erung Der MDKI, a novel receptor tyrosine kinase
US6565842B1 (en) * 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
WO1997010337A1 (en) 1995-09-15 1997-03-20 Baylor College Of Medicine Steroid receptor coactivator compositions and methods of use
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
EP0904366A1 (en) 1996-04-01 1999-03-31 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
AU729158B2 (en) 1997-01-31 2001-01-25 Genentech Inc. O-fucosyltransferase
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
WO1999010484A1 (en) * 1997-08-26 1999-03-04 Genentech, Inc. Rtd receptor
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
PT981618E (pt) 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
WO1998055615A1 (en) 1997-06-05 1998-12-10 The University Of Texas Board Or Regents Apaf-1, the ced-4 human homolog, an activator of caspase-3
EP2083079A1 (en) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
AU8569698A (en) * 1997-07-11 1999-02-08 Brandeis University Method of inducing apoptosis by reducing the level of thiamin
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
WO1999036535A1 (en) 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
WO1999064461A2 (en) * 1998-06-12 1999-12-16 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US6368793B1 (en) * 1998-10-14 2002-04-09 Microgenomics, Inc. Metabolic selection methods
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1124961B9 (en) * 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
US6982153B1 (en) 1998-12-03 2006-01-03 Targanta Therapeutics, Inc. DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
EP1192258A2 (en) * 1999-06-16 2002-04-03 Icos Corporation Human poly(adp-ribose) polymerase 2 materials and methods
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
US20030138771A1 (en) * 1999-09-30 2003-07-24 Jerry Pelletier DNA sequences from S. pneumoniae bacteriophage DP1 that encode anti-microbal polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1230552B1 (en) * 1999-11-16 2006-01-11 Genentech, Inc. Elisa for vegf
DE60117781T2 (de) 2000-04-21 2006-11-23 Amgen Inc., Thousand Oaks Peptidderivate des apolipoproteins-a1/aii
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
HK1052314A1 (zh) * 2000-08-11 2003-09-11 Favrille, Inc. 改变t细胞介导的病理的方法和组合物
EP1921088B1 (en) 2001-05-11 2014-10-08 Amgen Inc. Peptides and related molecules that bind to tall-1
DK2322229T3 (en) 2001-10-10 2017-03-27 Novo Nordisk As Remodeling and Glycoconjugation of Factor IX
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
ES2395014T3 (es) 2002-08-28 2013-02-07 Dyax Corp. Métodos para conservar órganos y tejidos
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
TW200526194A (en) * 2003-10-22 2005-08-16 Merz Pharma Gmbh & Co Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic Aβ peptides in amyloidopathies
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
CN1997893A (zh) * 2004-04-16 2007-07-11 健泰科生物技术公司 抗体测定法
CN102229609A (zh) 2004-05-13 2011-11-02 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
WO2005114218A2 (en) * 2004-05-15 2005-12-01 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
EP1755609A1 (en) * 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
WO2006010057A2 (en) * 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
NZ588430A (en) 2004-12-22 2012-10-26 Genentech Inc Methods for producing soluble multi-membrane-spanning proteins
CA2598409A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
AU2007357448B2 (en) * 2006-09-18 2012-09-06 Compugen Ltd Bioactive peptides and method of using same
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
MX2009003562A (es) 2006-10-04 2009-04-15 Genentech Inc Ensayo elisa para la deteccion de vegf.
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
EP2081602A2 (en) * 2006-10-25 2009-07-29 Amgen Inc. Toxin peptide therapeutic agents
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
US8420779B2 (en) * 2007-05-22 2013-04-16 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
JP5355561B2 (ja) 2007-07-12 2013-11-27 コンピュゲン エルティーディー． 生物活性ペプチドおよびその使用方法
SI2489731T1 (sl) 2007-07-26 2014-12-31 Amgen Inc. Patent Operations, M/S 28-2-C Modificirani encimi lecitin-holesterol aciltransferaze
EP2201024A1 (en) 2007-08-28 2010-06-30 Ramot At Tel Aviv University Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site
PL2808343T3 (pl) 2007-12-26 2019-11-29 Xencor Inc Warianty Fc ze zmienionym wiązaniem do FcRn
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
PE20120602A1 (es) 2009-03-24 2012-05-21 Gilead Calistoga Llc ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
MX2011011036A (es) * 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
DK2494356T3 (en) * 2009-10-26 2017-05-15 Genentech Inc ASSAYS FOR THE DETECTION OF ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE OF ANAPHYLAXY
EP2496567B1 (en) 2009-11-05 2017-07-12 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
CA2798080C (en) 2010-05-17 2020-08-25 Incozen Therapeutics Pvt. Ltd. 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2011160082A2 (en) 2010-06-17 2011-12-22 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012030738A2 (en) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
AP2013007173A0 (en) 2011-03-16 2013-10-31 Amgen Inc Potent and selective inhibitors of NAV1.3 and NAV1.7
CA2834552A1 (en) 2011-04-29 2012-11-01 Bristol-Myers Squibb Company Ip-10 antibody dosage escalation regimens
MX365160B (es) 2011-05-04 2019-05-24 Rhizen Pharmaceuticals Sa Compuestos novedosos como moduladores de proteína cinasas.
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
JO3625B1 (ar) 2011-09-22 2020-08-27 Amgen Inc بروتينات رابطة للأنتيجين cd27l
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
UY34656A (es) 2012-03-05 2013-10-31 Gilead Calistoga Llc Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación
WO2013142796A2 (en) 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
CN104334583A (zh) 2012-03-28 2015-02-04 弗·哈夫曼-拉罗切有限公司 抗-hcmv特应抗体及其用途
JP6192708B2 (ja) 2012-03-30 2017-09-06 ライゼン・ファーマシューティカルズ・エスアー Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
WO2014114801A1 (en) 2013-01-25 2014-07-31 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20150369821A1 (en) 2013-02-06 2015-12-24 Pieris Ag Novel lipocalin-mutein assays for measuring hepcidin concentration
AU2014218318B2 (en) 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
ES2993671T3 (en) 2013-03-15 2025-01-03 Univ Texas Peptide fttftvt for use in treating fibrosis
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
ES2753950T3 (es) 2013-03-15 2020-04-15 Amgen Res Munich Gmbh Moléculas de unión monocatenarias que comprenden ABP del extremo N
EP2951203B1 (en) 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
NZ753995A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
WO2015036956A1 (en) 2013-09-12 2015-03-19 Institut National De La Sante Et De La Recherche Medicale Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
EP3044323B1 (en) 2013-09-13 2022-04-06 F. Hoffmann-La Roche AG Methods for detecting and quantifying host cell protein in cell lines
JP6751344B2 (ja) 2013-09-13 2020-09-02 ジェネンテック， インコーポレイテッド 精製された組み換えポリペプチドを含む方法及び組成物
ES2859604T3 (es) 2013-10-11 2021-10-04 Oxford Bio Therapeutics Ltd Anticuerpos conjugados contra LY75 para el tratamiento del cáncer
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
SG11201604825VA (en) 2013-12-20 2016-07-28 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
AU2015207665B2 (en) 2014-01-17 2021-04-15 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
CA2939626C (en) 2014-02-20 2023-01-17 Allergan, Inc. Complement component c5 antibodies
RU2018135371A (ru) 2014-02-27 2018-12-10 Аллерган, Инк. АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
US11661462B2 (en) 2014-07-31 2023-05-30 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
ES2980787T3 (es) 2014-07-31 2024-10-03 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
AU2016230018A1 (en) 2015-03-06 2017-09-21 Genentech, Inc. Ultrapurified DsbA and DsbC and methods of making and using the same
WO2016149537A1 (en) 2015-03-17 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bank vole prion protein as a broad-spectrum substrate for rt-quic-based detection and discrimination of prion strains
US10851144B2 (en) 2015-04-10 2020-12-01 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP4276116A3 (en) 2015-04-17 2024-01-17 Amgen Research (Munich) GmbH Bispecific antibody constructs for cdh3 and cd3
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EP3932953A1 (en) 2015-08-28 2022-01-05 F. Hoffmann-La Roche AG Anti-hypusine antibodies and uses thereof
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
MY195542A (en) 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
TWI748984B (zh) 2016-02-03 2021-12-11 德商安美基研究（慕尼黑）公司 Bcma及cd3雙特異性t細胞嚙合抗體構築體
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
EP3808764A1 (en) 2016-05-04 2021-04-21 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
KR102481704B1 (ko) 2016-05-16 2022-12-27 다케다 파머수티컬 컴패니 리미티드 항-인자 ix 파두아 항체
JP7316930B2 (ja) 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
JP7105238B2 (ja) 2017-01-18 2022-07-22 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体に対するイディオタイプ抗体及びそれらの使用
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
JP7325936B2 (ja) 2017-05-05 2023-08-15 アムジエン・インコーポレーテツド 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物
WO2019075270A1 (en) 2017-10-12 2019-04-18 Amesino Llc VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
CN111315780A (zh) 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
JP2021522286A (ja) 2018-04-30 2021-08-30 メディミューン リミテッド 凝集体を標的とし、一掃するためのコンジュゲート
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
MY208638A (en) 2018-07-02 2025-05-21 Amgen Inc Anti-steap1 antigen-binding protein
EP3830121A1 (en) 2018-07-30 2021-06-09 Amgen Research (Munich) GmbH Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
AR117650A1 (es) 2018-10-11 2021-08-18 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecíficos
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
MX2021014644A (es) 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
CN114555634B (zh) 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
WO2021050640A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
EP4058485A1 (en) 2019-11-13 2022-09-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
CN115461375A (zh) 2020-04-30 2022-12-09 基因泰克公司 Kras特异性抗体及其用途
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
EP4157874A2 (en) 2020-05-29 2023-04-05 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
AU2021285802A1 (en) 2020-06-01 2022-12-08 Genentech, Inc. Methods for making extracellular vesicles and uses thereof
US12497463B2 (en) 2020-06-23 2025-12-16 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-CD38 antibody and use thereof
IL299121A (en) 2020-07-14 2023-02-01 Hoffmann La Roche Tests for fixed dose combinations
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
TW202313681A (zh) 2021-04-02 2023-04-01 美商安進公司 Ｍａｇｅｂ２結合構建體
AU2022269312A1 (en) 2021-05-06 2023-10-19 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
CN113372514B (zh) * 2021-06-22 2022-06-14 安徽农业大学 一种刀豆蛋白聚合物水凝胶的制备方法、制得的水凝胶及其应用
AU2023268600A1 (en) 2022-05-12 2024-11-07 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
AU2023343470A1 (en) 2022-09-14 2025-02-06 Amgen Inc. Bispecific molecule stabilizing composition
TW202510911A (zh) 2023-06-14 2025-03-16 美商安進公司 Ｔ細胞接合劑掩蔽分子

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3574062A (en) * 1967-04-20 1971-04-06 Beckman Instruments Inc Method of immobilizing enzymes and product
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (cg-RX-API-DMAC7.html) * 1967-12-20 1972-03-06 Pharmacia Ab
FR1603393A (cg-RX-API-DMAC7.html) * 1967-12-27 1971-04-13
DE1908290C3 (de) * 1969-02-19 1982-04-08 Boehringer Mannheim Gmbh, 6800 Mannheim Acrylamid-mischpolymerisat
GB1316990A (en) * 1970-09-17 1973-05-16 Roche Products Ltd Imidazolyl derivatives
AT317424B (de) * 1971-06-09 1974-08-26 Boehringer Mannheim Gmbh Verfahren zur Herstellung von trägergebundenen Proteinen

Also Published As

Publication number Publication date
SE420498B (sv) 1981-10-12
IL43476A (en) 1976-03-31
HU169972B (cg-RX-API-DMAC7.html) 1977-03-28
JPS5749197B2 (cg-RX-API-DMAC7.html) 1982-10-20
DK141555B (da) 1980-04-21
SU524521A3 (ru) 1976-08-05
US3969287A (en) 1976-07-13
CA1023287A (en) 1977-12-27
ZA739318B (en) 1974-11-27
CH619003A5 (cg-RX-API-DMAC7.html) 1980-08-29
IT1045912B (it) 1980-06-10
JPS4986587A (cg-RX-API-DMAC7.html) 1974-08-19
DK141555C (da) 1980-09-22

Similar Documents

Publication Publication Date Title
BE808354A (fr) Proteine fixee sur un support et procede de fabrication
IT987003B (it) Stazione di controllo e metodo per la sua fabbricazione
BE799903A (fr) Raquette et son procede de fabrication
BE797145A (fr) Feuilles continues fibreuses absorbantes et procede de fabrication
BE796460A (fr) Transistor bipolaire et procede de fabrication de celui-ci
IT976951B (it) Termometro numerico e metodo per fabbricarlo
BE802375A (fr) Procede de fabrication d'un panneau chauffant transparent et panneau en resultant
BE797255A (fr) Premiere de chaussure et son procede de fabrication
BE800944A (fr) Amino-alcools
BE794022A (fr) Support pour catalyseur et procede de fabrication
BE795445A (fr) Convecteur et son procede de fabrication
FR2327480A1 (fr) Tuyau et son procede de fabrication
BE804332A (fr) Support d'information et son procede de fabrication
BE801096A (fr) Procede de fabrication de diphenylamine et de ses derives
IT984232B (it) Gabbie per cuscinetti e metodo per la produzione di tali gabbie
BE807927A (fr) Procede et appareil de fabrication d'elements de renforcement
BE811323A (fr) Support de catalyseur et procede de fabrication de ce support
CH553894A (fr) Panneau isothermique et procede de fabrication de ce panneau.
BE801184A (fr) Transducteurs magnetiques perfectionnes et leur procede de fabrication
IT1014023B (it) Lipasi microbica e procedimento per la sua produzione
BE801095A (fr) Procede de fabrication de diphenylamine et de ses derives
BE795592A (fr) Installation et procede d'alcoylation
BE808245A (fr) Procede de fabrication de vincamone et de vincanol
BE801535A (fr) Tertiobutyl-4 perbenzoate de tertiobutyle et son procede de fabrication
IT994621B (it) Pneumatico radiale e procedimento per la sua fabbricazion

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: BOEHRINGER MANNHEIM G.M.B.H.

Effective date: 19931207